Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Christopher Michael Reid Jr

Co-Author

This page shows the publications co-authored by Christopher Reid and Deepak Bhatt.
Connection Strength

0.839
  1. Prevalence and Outcomes of Undiagnosed Peripheral Arterial Disease Among High Risk Patients in Australia: An Australian REACH Sub-Study. Heart Lung Circ. 2019 Jun; 28(6):939-945.
    View in: PubMed
    Score: 0.195
  2. Outcomes and excess costs among patients with cardiovascular disease. Heart Lung Circ. 2013 Sep; 22(9):724-30.
    View in: PubMed
    Score: 0.137
  3. Outcomes from the REACH Registry for Australian general practice patients with or at high risk of atherothrombosis. Med J Aust. 2012 Feb 20; 196(3):193-7.
    View in: PubMed
    Score: 0.127
  4. Geographic variation and risk factors for systemic and limb ischemic events in patients with symptomatic peripheral artery disease: Insights from the REACH Registry. Clin Cardiol. 2017 Sep; 40(9):710-718.
    View in: PubMed
    Score: 0.046
  5. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in high vascular risk. Heart. 2017 09; 103(17):1339-1346.
    View in: PubMed
    Score: 0.045
  6. Clinical outcomes in patients with stable coronary artery disease with vs. without a history of myocardial revascularization. Eur Heart J Qual Care Clin Outcomes. 2016 Jan 01; 2(1):23-32.
    View in: PubMed
    Score: 0.042
  7. Predictors of health care use among patients with or at high risk of atherothrombotic disease: two-year follow-up data. Int J Cardiol. 2014 Jul 15; 175(1):72-7.
    View in: PubMed
    Score: 0.037
  8. The impact of lost therapeutic benefit (LTB) in high-risk hypertensive patients: 2-year follow-up data from the Australian REACH registry. Cardiovasc Ther. 2013 Dec; 31(6):370-6.
    View in: PubMed
    Score: 0.036
  9. An international model to predict recurrent cardiovascular disease. Am J Med. 2012 Jul; 125(7):695-703.e1.
    View in: PubMed
    Score: 0.033
  10. Cost-effectiveness of optimizing use of statins in Australia: using outpatient data from the REACH Registry. Clin Ther. 2011 Oct; 33(10):1456-65.
    View in: PubMed
    Score: 0.031
  11. Is it cost-effective to increase aspirin use in outpatient settings for primary or secondary prevention? Simulation data from the REACH Registry Australian Cohort. Cardiovasc Ther. 2013 Feb; 31(1):45-52.
    View in: PubMed
    Score: 0.030
  12. The economic implications of treating atherothrombotic disease in Australia, from the government perspective. Clin Ther. 2010 Jan; 32(1):119-32; discussion 106-7.
    View in: PubMed
    Score: 0.027
  13. Predictors of annual pharmaceutical costs in Australia for community-based individuals with, or at risk of, cardiovascular disease: analysis of Australian data from the REACH registry. Am J Cardiovasc Drugs. 2010; 10(2):85-94.
    View in: PubMed
    Score: 0.027
  14. Drug treatment and cost of cardiovascular disease in Australia. Cardiovasc Ther. 2009; 27(3):164-72.
    View in: PubMed
    Score: 0.026
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.